Infectious Disease

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1469256

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1469256

Dermatophytic Onychomycosis Therapeutics Market by Product Type, End-Users, and Geography : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

PUBLISHED: April 15, 2024

PAGES: 336 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Persistence Market Research recently conducted an in-depth analysis of the Dermatophytic Onychomycosis Therapeutics Market, resulting in a comprehensive report that delves extensively into its global landscape. This detailed publication provides valuable insights into the market's dynamics, trends, opportunities, and challenges, offering a thorough overview of its structure. With the support of exclusive data and statistics, the research predicts the anticipated growth trajectory of the Dermatophytic Onychomycosis Therapeutics Market spanning from 2024 to 2031.

The global dermatophytic onychomycosis therapeutics market is worth US$ US$ 6.64 Bn billion in 2024, with a projected CAGR of 6.5% through 2031, reaching US$ 10.30 billion.

Key Insights:

Dermatophytic Onychomycosis Therapeutics Market Size (2024): US$ 6.64 Bn
Projected Market Value (2031): US$ 10.30 Bn
Global Market Growth Rate (CAGR2024-2031):6.5%
Share of Top 5 Countries: 61%

Dermatophytic Onychomycosis Therapeutics Market - Report Scope

The dermatophytic onychomycosis therapeutics market focuses on addressing fungal infections affecting the nails, offering solutions for both treatment and prevention. This report examines the scope of the market, detailing the efficacy and innovation of various therapeutic interventions.

Market Growth Drivers

The dermatophytic onychomycosis therapeutics market is primarily driven by the rising incidence of fungal nail infections globally. With increasing awareness of fungal diseases and their impact on overall health, there is a growing demand for effective treatment options. Additionally, factors such as aging populations, prevalence of diabetes, and lifestyle changes contribute to the market's growth.

Market Restraints

Despite the market's growth potential, challenges such as limited efficacy of existing treatments and high recurrence rates hinder market expansion. Additionally, regulatory hurdles and safety concerns associated with some therapeutic agents pose constraints for market players.

Opportunities

The dermatophytic onychomycosis therapeutics market presents opportunities for innovation and development of novel treatment modalities. Advancements in drug delivery technologies, such as topical formulations and combination therapies, offer avenues for improved patient outcomes. Furthermore, strategic collaborations and partnerships can facilitate research and development efforts, leading to the introduction of more effective and safer therapeutic options.

Key Questions Answered in Report::

What is the current size and projected growth of the dermatophytic onychomycosis therapeutics market?
What are the primary drivers fueling market growth in this segment?
What challenges are hindering the expansion of the dermatophytic onychomycosis therapeutics market?
What opportunities exist for manufacturers and stakeholders in this market?
How are regulatory frameworks and safety considerations impacting the development and commercialization of therapeutics for fungal nail infections?

Competitive Intelligence and Business Strategy

Key dermatophytic onychomycosis therapeutic manufacturers are expanding globally by gaining FDA approval and partnering with local distributors. Examples include Almirall S.A.'s agreement with Kaken Pharmaceutical for efinaconazole in Europe and Erchonia Corp.'s FDA clearance for the Lunula Laser in 2016.

Key Companies Profiled

Bausch Health
Galderma S.A.
Novartis AG
Pfizer, Inc.
Moberg Pharma AB
Bayer AG
Dr. Reddy's Laboratories Ltd.
Cipla Ltd.
Medimetriks Pharmaceuticals, Inc.
Sanofi S.A.
GlaxoSmithKline Plc.
Teva Pharmaceutical industries Ltd.
Cardinal Health Inc.
Viatris Inc.
Almirall, S.A

Dermatophytic Onychomycosis Therapeutics Market Segmentation:

Dermatophytic Onychomycosis Therapeutics Market by Treatment Type:

Dermatophytic Onychomycosis Therapeutic Drugs

oOral

oTopical

Rx
OTC
Dermatophytic Onychomycosis Therapeutic Lasers

oC02 Ablative Lasers

oNd:YAG Lasers

oDual-wave length near-infrared Lasers

Photodynamic Therapy

Dermatophytic Onychomycosis Therapeutics Market by Indication:

Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis

Dermatophytic Onychomycosis Therapeutics Market by Gender:

Male
Female

Dermatophytic Onychomycosis Therapeutics Market by Age Group:

0-18 Years
18-39 Years
40-64 Years
65 Years and Above

Dermatophytic Onychomycosis Therapeutics Market by End User:

Institutional Sales

oHospitals

oDermatology Clinics

Retail Sales

oRetail Pharmacies

oDrug Stores

oMail Order Pharmacies & Online Sales

Dermatophytic Onychomycosis Therapeutics Market by Region:

North America
Latin America Europe
South Asia
East Asia Oceania
Middle East & Africa

Product Code: PMRREP5840

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Disease Epidemiology
4.2. Treatment Regime (Prescription Pattern)
4.3. Key Regulation Scenario
4.4. Pipeline Analysis
4.5. Reimbursement Scenario

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Per Capita Healthcare Expenditure Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Social Determinants
- 5.2.2. Growing Elderly Population and future Outlook
- 5.2.3. New Market Development For Advanced Products Exhibit Lucrative Growth Opportunities
5.3. Value Chain
5.4. Market Dynamics
- 5.4.1. Drivers
- 5.4.2. Restraints
- 5.4.3. Opportunity Analysis

6. COVID19 - Impact Analysis

6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
- 6.4.1. Revenue By Treatment
- 6.4.2. Revenue By Indication
- 6.4.3. Revenue By Gender
- 6.4.4. Revenue By Age Group
- 6.4.5. Revenue By Distribution Channel
- 6.4.6. Revenue By Country
6.5. Recovery Scenario - Short term, Midterm and Long Term Impact

7. Global Dermatophytic Onychomycosis Therapeutics Market - Pricing Analysis

7.1. Regional Pricing Analysis By Product
7.2. Pricing Break-up
- 7.2.1. Manufacturer Level Pricing
- 7.2.2. Distributor Level Pricing
7.3. Average Pricing Analysis Benchmark

8. Global Dermatophytic Onychomycosis Therapeutics Market (Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2031

8.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
8.2. Current and Future Market Value (US$ Mn) Projections, 2024-2031
- 8.2.1. Y-o-Y Growth Trend Analysis
- 8.2.2. Absolute $ Opportunity Analysis

9. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, By Treatment

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Treatment, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment, 2024-2031
- 9.3.1. Drugs
  - 9.3.1.1. Oral
    - 9.3.1.1.1. Rx
    - 9.3.1.1.2. OTC
  - 9.3.1.2. Topical
    - 9.3.1.2.1. Rx
    - 9.3.1.2.2. OTC
- 9.3.2. Lasers
  - 9.3.2.1. Neodymium: yttrium-aluminium-garnet laser (Nd:YAG)
  - 9.3.2.2. Dual-wavelength near-infrared laser
  - 9.3.2.3. CO2 Ablative Laser
- 9.3.3. Photodynamic Therapy
9.4. Market Attractiveness Analysis By Treatment

10. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, by Indication

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) By Indication, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2024-2031
- 10.3.1. Distal Subungual Onychomycosis
- 10.3.2. White Superficial Onychomycosis
- 10.3.3. Proximal Subungual Onychomycosis
- 10.3.4. Candida Onychomycosis
- 10.3.5. Total Dystrophic Onychomycosis
10.4. Market Attractiveness Analysis By Indication

11. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, by Gender

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Gender, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Gender, 2024-2031
- 11.3.1. Male
- 11.3.2. Female
11.4. Market Attractiveness Analysis By Gender

12. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, by Age Group

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Age Group, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Age Group, 2024-2031
- 12.3.1. 0-18 Years
- 12.3.2. 18-39 Years
- 12.3.3. 40-64 Years
- 12.3.4. 65 Years and Above
12.4. Market Attractiveness Analysis By Gender

13. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, by Distribution Channel

13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2031
- 13.3.1. Institutional Sales
  - 13.3.1.1. Hospitals
  - 13.3.1.2. Dermatology Clinics
- 13.3.2. Retail Sales
  - 13.3.2.1. Retail Pharmacies
  - 13.3.2.2. Drugs Stores
- 13.3.3. Mail Order Pharmacies & Online Sales
13.4. Market Attractiveness Analysis By Gender

14. Global Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031, by Region

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2013 - 2021
14.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2031
- 14.3.1. North America
- 14.3.2. Latin America
- 14.3.3. Europe
- 14.3.4. East Asia
- 14.3.5. South Asia
- 14.3.6. Oceania
- 14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis By Region

15. North America Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 15.3.1. By Country
  - 15.3.1.1. U.S.
  - 15.3.1.2. Canada
- 15.3.2. By Treatment
- 15.3.3. By Indication
- 15.3.4. By Gender
- 15.3.5. By Age group
- 15.3.6. By Distribution Channel
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis

16. Latin America Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 16.3.1. By Country
  - 16.3.1.1. Brazil
  - 16.3.1.2. Mexico
  - 16.3.1.3. Argentina
  - 16.3.1.4. Rest of Latin America
- 16.3.2. By Treatment
- 16.3.3. By Indication
- 16.3.4. By Gender
- 16.3.5. By Age group
- 16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis

17. Europe Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 17.3.1. By Country
  - 17.3.1.1. Germany
  - 17.3.1.2. Italy
  - 17.3.1.3. France
  - 17.3.1.4. U.K.
  - 17.3.1.5. Spain
  - 17.3.1.6. BENELUX
  - 17.3.1.7. Russia
  - 17.3.1.8. Rest of Europe
- 17.3.2. By Treatment
- 17.3.3. By Indication
- 17.3.4. By Gender
- 17.3.5. By Age group
- 17.3.6. By Distribution Channel
17.4. Market Attractiveness Analysis
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis

18. South Asia Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 18.3.1. By Country
  - 18.3.1.1. India
  - 18.3.1.2. Thailand
  - 18.3.1.3. Indonesia
  - 18.3.1.4. Malaysia
  - 18.3.1.5. Rest of South Asia
- 18.3.2. By Treatment
- 18.3.3. By Indication
- 18.3.4. By Gender
- 18.3.5. By Age group
- 18.3.6. By Distribution Channel
18.4. Market Attractiveness Analysis
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis

19. Oceania Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 19.3.1. By Country
  - 19.3.1.1. Australia
  - 19.3.1.2. New Zealand
- 19.3.2. By Treatment
- 19.3.3. By Indication
- 19.3.4. By Gender
- 19.3.5. By Age group
- 19.3.6. By Distribution Channel
19.4. Market Attractiveness Analysis
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Dermatophytic Onychomycosis Therapeutics Market Analysis 2019-2023 and Forecast 2024-2031

20.1. Introduction
20.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
20.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2031
- 20.3.1. By Country
  - 20.3.1.1. GCC Countries
  - 20.3.1.2. Turkey
  - 20.3.1.3. South Africa
  - 20.3.1.4. Rest of Middle East and Africa
- 20.3.2. By Treatment
- 20.3.3. By Indication
- 20.3.4. By Gender
- 20.3.5. By Age group
- 20.3.6. By Distribution Channel
20.4. Market Attractiveness Analysis
20.5. Key Market Participants - Intensity Mapping
20.6. Drivers and Restraints - Impact Analysis

21. Key and Emerging Countries Dermatophytic Onychomycosis Therapeutics Market Analysis 2022 & 2031

21.1. Introduction
- 21.1.1. Market Value Proportion Analysis, By Key Countries
- 21.1.2. Global Vs. Country Growth Comparison
21.2. U.S. Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.2.1. By Treatment
- 21.2.2. By Indication
- 21.2.3. By Gender
- 21.2.4. By Age group
- 21.2.5. By Distribution Channel
21.3. Canada Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.3.1. By Treatment
- 21.3.2. By Indication
- 21.3.3. By Gender
- 21.3.4. By Age group
- 21.3.5. By Distribution Channel
21.4. Brazil Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.4.1. By Treatment
- 21.4.2. By Indication
- 21.4.3. By Gender
- 21.4.4. By Age group
- 21.4.5. By Distribution Channel
21.5. Mexico Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.5.1. By Treatment
- 21.5.2. By Indication
- 21.5.3. By Gender
- 21.5.4. By Age group
- 21.5.5. By Distribution Channel
21.6. Argentina Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.6.1. By Treatment
- 21.6.2. By Indication
- 21.6.3. By Gender
- 21.6.4. By Age group
- 21.6.5. By Distribution Channel
21.7. Germany Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.7.1. By Treatment
- 21.7.2. By Indication
- 21.7.3. By Gender
- 21.7.4. By Age group
- 21.7.5. By Distribution Channel
21.8. France Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.8.1. By Treatment
- 21.8.2. By Indication
- 21.8.3. By Gender
- 21.8.4. By Age group
- 21.8.5. By Distribution Channel
21.9. U.K. Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.9.1. By Treatment
- 21.9.2. By Indication
- 21.9.3. By Gender
- 21.9.4. By Age group
- 21.9.5. By Distribution Channel
21.10. Spain Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.10.1. By Treatment
- 21.10.2. By Indication
- 21.10.3. By Gender
- 21.10.4. By Age group
- 21.10.5. By Distribution Channel
21.11. BENELUX Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.11.1. By Treatment
- 21.11.2. By Indication
- 21.11.3. By Gender
- 21.11.4. By Age group
- 21.11.5. By Distribution Channel
21.12. Russia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.12.1. By Treatment
- 21.12.2. By Indication
- 21.12.3. By Gender
- 21.12.4. By Age group
- 21.12.5. By Distribution Channel
21.13. India Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.13.1. By Treatment
- 21.13.2. By Indication
- 21.13.3. By Gender
- 21.13.4. By Age group
- 21.13.5. By Distribution Channel
21.14. Thailand Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.14.1. By Treatment
- 21.14.2. By Indication
- 21.14.3. By Gender
- 21.14.4. By Age group
- 21.14.5. By Distribution Channel
21.15. Indonesia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.15.1. By Treatment
- 21.15.2. By Indication
- 21.15.3. By Gender
- 21.15.4. By Age group
- 21.15.5. By Distribution Channel
21.16. Malaysia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.16.1. By Treatment
- 21.16.2. By Indication
- 21.16.3. By Gender
- 21.16.4. By Age group
- 21.16.5. By Distribution Channel
21.17. ASEAN Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.17.1. By Treatment
- 21.17.2. By Indication
- 21.17.3. By Gender
- 21.17.4. By Age group
- 21.17.5. By Distribution Channel
21.18. China Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.18.1. By Treatment
- 21.18.2. By Indication
- 21.18.3. By Gender
- 21.18.4. By Age group
- 21.18.5. By Distribution Channel
21.19. Japan Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.19.1. By Treatment
- 21.19.2. By Indication
- 21.19.3. By Gender
- 21.19.4. By Age group
- 21.19.5. By Distribution Channel
21.20. South Korea Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.20.1. By Treatment
- 21.20.2. By Indication
- 21.20.3. By Gender
- 21.20.4. By Age group
- 21.20.5. By Distribution Channel
21.21. Australia Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.21.1. By Treatment
- 21.21.2. By Indication
- 21.21.3. By Gender
- 21.21.4. By Age group
- 21.21.5. By Distribution Channel
21.22. New Zealand Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.22.1. By Treatment
- 21.22.2. By Indication
- 21.22.3. By Gender
- 21.22.4. By Age group
- 21.22.5. By Distribution Channel
21.23. GCC Countries Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.23.1. By Treatment
- 21.23.2. By Indication
- 21.23.3. By Gender
- 21.23.4. By Age group
- 21.23.5. By Distribution Channel
21.24. South Africa Dermatophytic Onychomycosis Therapeutics Market Analysis
- 21.24.1. By Treatment
- 21.24.2. By Indication
- 21.24.3. By Gender
- 21.24.4. By Age group
- 21.24.5. By Distribution Channel

22. Market Structure Analysis

22.1. Market Analysis by Tier of Companies
22.2. Market Concentration
22.3. Market Share Analysis of Top Players
22.4. Market Presence Analysis
- 22.4.1. By Regional footprint of Players
- 22.4.2. Product foot print by Players
- 22.4.3. Channel Foot Print by Players

23. Competition Analysis

23.1. Competition Dashboard
23.2. Competition Benchmarking
23.3. Competition Deep Dive
- 23.3.1. Bausch Health
  - 23.3.1.1. Overview
  - 23.3.1.2. Product Portfolio
  - 23.3.1.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.1.4. Sales Footprint
  - 23.3.1.5. Strategy Overview
    - 23.3.1.5.1. Marketing Strategy
    - 23.3.1.5.2. Product Strategy
    - 23.3.1.5.3. Channel Strategy
- 23.3.2. Galderma S.A.
  - 23.3.2.1. Overview
  - 23.3.2.2. Product Portfolio
  - 23.3.2.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.2.4. Sales Footprint
  - 23.3.2.5. Strategy Overview
    - 23.3.2.5.1. Marketing Strategy
    - 23.3.2.5.2. Product Strategy
    - 23.3.2.5.3. Channel Strategy
- 23.3.3. Novartis AG
  - 23.3.3.1. Overview
  - 23.3.3.2. Product Portfolio
  - 23.3.3.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.3.4. Sales Footprint
  - 23.3.3.5. Strategy Overview
    - 23.3.3.5.1. Marketing Strategy
    - 23.3.3.5.2. Product Strategy
    - 23.3.3.5.3. Channel Strategy
- 23.3.4. Pfizer, Inc.
  - 23.3.4.1. Overview
  - 23.3.4.2. Product Portfolio
  - 23.3.4.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.4.4. Sales Footprint
  - 23.3.4.5. Strategy Overview
    - 23.3.4.5.1. Marketing Strategy
    - 23.3.4.5.2. Product Strategy
    - 23.3.4.5.3. Channel Strategy
- 23.3.5. Moberg Pharma AB
  - 23.3.5.1. Overview
  - 23.3.5.2. Product Portfolio
  - 23.3.5.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.5.4. Sales Footprint
  - 23.3.5.5. Strategy Overview
    - 23.3.5.5.1. Marketing Strategy
    - 23.3.5.5.2. Product Strategy
    - 23.3.5.5.3. Channel Strategy
- 23.3.6. Bayer AG
  - 23.3.6.1. Overview
  - 23.3.6.2. Product Portfolio
  - 23.3.6.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.6.4. Sales Footprint
  - 23.3.6.5. Strategy Overview
    - 23.3.6.5.1. Marketing Strategy
    - 23.3.6.5.2. Product Strategy
    - 23.3.6.5.3. Channel Strategy
- 23.3.7. Dr. Reddy's Laboratories Ltd.
  - 23.3.7.1. Overview
  - 23.3.7.2. Product Portfolio
  - 23.3.7.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.7.4. Sales Footprint
  - 23.3.7.5. Strategy Overview
    - 23.3.7.5.1. Marketing Strategy
    - 23.3.7.5.2. Product Strategy
    - 23.3.7.5.3. Channel Strategy
- 23.3.8. Cipla Ltd.
  - 23.3.8.1. Overview
  - 23.3.8.2. Product Portfolio
  - 23.3.8.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.8.4. Sales Footprint
  - 23.3.8.5. Strategy Overview
    - 23.3.8.5.1. Marketing Strategy
    - 23.3.8.5.2. Product Strategy
    - 23.3.8.5.3. Channel Strategy
- 23.3.9. Medimetriks Pharmaceuticals, Inc.
  - 23.3.9.1. Overview
  - 23.3.9.2. Product Portfolio
  - 23.3.9.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.9.4. Sales Footprint
  - 23.3.9.5. Strategy Overview
    - 23.3.9.5.1. Marketing Strategy
    - 23.3.9.5.2. Product Strategy
    - 23.3.9.5.3. Channel Strategy
- 23.3.10. Sanofi S.A.
  - 23.3.10.1. Overview
  - 23.3.10.2. Product Portfolio
  - 23.3.10.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.10.4. Sales Footprint
  - 23.3.10.5. Strategy Overview
    - 23.3.10.5.1. Marketing Strategy
    - 23.3.10.5.2. Product Strategy
    - 23.3.10.5.3. Channel Strategy
- 23.3.11. GlaxoSmithKline Plc.
  - 23.3.11.1. Overview
  - 23.3.11.2. Product Portfolio
  - 23.3.11.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.11.4. Sales Footprint
  - 23.3.11.5. Strategy Overview
    - 23.3.11.5.1. Marketing Strategy
    - 23.3.11.5.2. Product Strategy
    - 23.3.11.5.3. Channel Strategy
- 23.3.12. Teva Pharmaceutical industries Ltd.
  - 23.3.12.1. Overview
  - 23.3.12.2. Product Portfolio
  - 23.3.12.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.12.4. Sales Footprint
  - 23.3.12.5. Strategy Overview
    - 23.3.12.5.1. Marketing Strategy
    - 23.3.12.5.2. Product Strategy
    - 23.3.12.5.3. Channel Strategy
- 23.3.13. Cardinal Health Inc.
  - 23.3.13.1. Overview
  - 23.3.13.2. Product Portfolio
  - 23.3.13.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.13.4. Sales Footprint
  - 23.3.13.5. Strategy Overview
    - 23.3.13.5.1. Marketing Strategy
    - 23.3.13.5.2. Product Strategy
    - 23.3.13.5.3. Channel Strategy
- 23.3.14. Viatris Inc.
  - 23.3.14.1. Overview
  - 23.3.14.2. Product Portfolio
  - 23.3.14.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.14.4. Sales Footprint
  - 23.3.14.5. Strategy Overview
    - 23.3.14.5.1. Marketing Strategy
    - 23.3.14.5.2. Product Strategy
    - 23.3.14.5.3. Channel Strategy
- 23.3.15. Almirall, S.A
  - 23.3.15.1. Overview
  - 23.3.15.2. Product Portfolio
  - 23.3.15.3. Profitability by Market Segments (Product/Channel/Region)
  - 23.3.15.4. Sales Footprint
  - 23.3.15.5. Strategy Overview
    - 23.3.15.5.1. Marketing Strategy
    - 23.3.15.5.2. Product Strategy
    - 23.3.15.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ